A Reproducible and Scalable Process for Manufacturing a Pfs48/45 Based Plasmodium falciparum Transmission-Blocking Vaccine
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Reproducible and Scalable Process for Manufacturing a Pfs48/45 Based Plasmodium falciparum Transmission-Blocking Vaccine
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-01-13
DOI
10.3389/fimmu.2020.606266
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- First-in-human, randomized, double-blind clinical trial of differentially adjuvanted PAMVAC, a vaccine candidate to prevent pregnancy-associated malaria
- (2019) Benjamin Mordmüller et al. CLINICAL INFECTIOUS DISEASES
- Comparative Genome Analysis of Lactococcus lactis Indicates Niche Adaptation and Resolves Genotype/Phenotype Disparity
- (2019) Michiel Wels et al. Frontiers in Microbiology
- Pfs230 and Pfs48/45 Fusion Proteins Elicit Strong Transmission-Blocking Antibody Responses Against Plasmodium falciparum
- (2019) Susheel K. Singh et al. Frontiers in Immunology
- The Plasmodium falciparum circumsporozoite protein produced in Lactococcus lactis is pure and stable
- (2019) Susheel K. Singh et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice
- (2018) Sofia E. Magnusson et al. IMMUNOLOGIC RESEARCH
- Lactococcus lactis provides an efficient platform for production of disulfide-rich recombinant proteins from Plasmodium falciparum
- (2018) Susheel K. Singh et al. Microbial Cell Factories
- Improved Titers against Influenza Drift Variants with a Nanoparticle Vaccine
- (2018) Vivek Shinde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and immunogenicity of Pfs25H-EPA/Alhydrogel, a transmission-blocking vaccine against Plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-escalation study in healthy Malian adults
- (2018) Issaka Sagara et al. LANCET INFECTIOUS DISEASES
- Controlled human malaria infection of healthy lifelong malaria-exposed adults to assess safety, immunogenicity and efficacy of the asexual blood stage malaria vaccine candidate GMZ2
- (2018) Jean Claude Dejon-Agobe et al. CLINICAL INFECTIOUS DISEASES
- The GMZ2 malaria vaccine: from concept to efficacy in humans
- (2017) Michael Theisen et al. Expert Review of Vaccines
- Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine
- (2017) Michael Theisen et al. Expert Review of Vaccines
- Naturally Acquired Antibodies Target the Glutamate-Rich Protein on Intact Merozoites and Predict Protection Against Febrile Malaria
- (2017) Ikhlaq Hussain Kana et al. JOURNAL OF INFECTIOUS DISEASES
- Construct design, production, and characterization of Plasmodium falciparum 48/45 R0.6C subunit protein produced in Lactococcus lactis as candidate vaccine
- (2017) Susheel K. Singh et al. Microbial Cell Factories
- Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display
- (2017) Susheel K. Singh et al. VACCINE
- Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children
- (2016) Ally Olotu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Naturally acquired immunity to sexual stage P. falciparum parasites
- (2016) WILL J. R. STONE et al. PARASITOLOGY
- Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice
- (2016) Karin Lövgren Bengtsson et al. VACCINE
- Synthetic TLR4 agonists enhance functional antibodies and CD4+ T-cell responses against the Plasmodium falciparum GMZ2.6C multi-stage vaccine antigen
- (2016) Susan L. Baldwin et al. VACCINE
- Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults
- (2016) Kawsar R. Talaat et al. PLoS One
- Genome-Wide Transcriptional Responses to Carbon Starvation in Nongrowing Lactococcus lactis
- (2015) Onur Ercan et al. APPLIED AND ENVIRONMENTAL MICROBIOLOGY
- A Plasmodium falciparum 48/45 single epitope R0.6C subunit protein elicits high levels of transmission blocking antibodies
- (2015) Susheel K. Singh et al. VACCINE
- Molecular and Metabolic Adaptations of Lactococcus lactis at Near-Zero Growth Rates
- (2014) Onur Ercan et al. APPLIED AND ENVIRONMENTAL MICROBIOLOGY
- A multi-stage malaria vaccine candidate targeting both transmission and asexual parasite life-cycle stages
- (2014) Michael Theisen et al. VACCINE
- Matrix-M™ adjuvanted envelope protein vaccine protects against lethal lineage 1 and 2 West Nile virus infection in mice
- (2014) Sofia E. Magnusson et al. VACCINE
- Matrix-M™ adjuvant: enhancing immune responses by ‘setting the stage’ for the antigen
- (2013) Karin Lövgren Bengtsson et al. Expert Review of Vaccines
- Recombinant protein expression inLactococcus lactisusing the P170 expression system
- (2013) Casper M. Jørgensen et al. FEMS MICROBIOLOGY LETTERS
- Immune enhancing properties of the novel Matrix-M™ adjuvant leads to potentiated immune responses to an influenza vaccine in mice
- (2013) Sofia E. Magnusson et al. VACCINE
- Measuring the blockade of malaria transmission – An analysis of the Standard Membrane Feeding Assay
- (2012) Thomas S. Churcher et al. INTERNATIONAL JOURNAL FOR PARASITOLOGY
- Lymph Node Macrophages
- (2012) Elizabeth E. Gray et al. Journal of Innate Immunity
- Matrix-M™ Adjuvant Induces Local Recruitment, Activation and Maturation of Central Immune Cells in Absence of Antigen
- (2012) Jenny M. Reimer et al. PLoS One
- Non-Apical Membrane Antigen 1 (AMA1) IgGs from Malian Children Interfere with Functional Activity of AMA1 IgGs as Judged by Growth Inhibition Assay
- (2011) Kazutoyo Miura et al. PLoS One
- A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2 – A GLURP–MSP3 fusion protein malaria vaccine candidate
- (2011) Susana Lousada-Dietrich et al. VACCINE
- Blood Stage Malaria Vaccine Eliciting High Antigen-Specific Antibody Concentrations Confers No Protection to Young Children in Western Kenya
- (2009) Bernhards R. Ogutu et al. PLoS One
- Generalized linear mixed models: a practical guide for ecology and evolution
- (2009) Benjamin M. Bolker et al. TRENDS IN ECOLOGY & EVOLUTION
- A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali
- (2009) Issaka Sagara et al. VACCINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now